Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The...
Retracing after gap up
More than 50% retraced alreday
Will probably fill Gap#2 with the next few days
A second target is fill gap#1 from june.
PT1 = 2,54 (filled)
PT2 = 1,56 (For Gap#2 fill)
Bonus PT3 = 1,12
Bonus PT4 = 0,60 (For gap #1 fill)
New data independently confirms and extends laboratory findings and expands safety profile of ATH434
new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological...
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder.
The company recently...